Westminster Health Forum

Since lockdown, we have been organising our full programme of conferences online. We will continue online until further notice, to ensure we play our part in helping our employees and delegates to remain safe during this time. We are pleased that so many key stakeholders, policymakers and other interested parties - both old friends and new delegates - are taking up the opportunity to discuss public policy issues and network at our impartial seminars. New events are coming on to our conference programme all the time. So there are plenty of opportunities for you to join us if you haven’t already, from wherever you are. For booking-related queries, or information on speaking, please email us at info@forumsupport.co.uk or contact us using one of the following numbers: +44 (0)7538736244 / +44 (0)7503591880 / +44 (0)7951044809.
For delegates already booked on, we will send you the online joining instructions (including links, event numbers and passwords) five working days before your conference. If you cannot find these in your inbox please email delegate.relations@forumsupport.co.uk

Next steps for tackling antimicrobial resistance - funding and incentives, prescribing, developing the global response, and learning from the pandemic

Morning, Monday, 30th November 2020


***Full-scale policy conference taking place online***

This conference will discuss priorities for tackling antimicrobial resistance, progress on the UK strategy, and global collaboration.


The discussion takes place following the launch of a new payment model for antibiotics earlier this year which incentivises pharmaceutical companies to develop innovative new treatments.


The conference is bringing stakeholders together with key policy officials who are due to attend from DHSC; the MHRA; HM Treasury; the NAO; Defra; DIT; the Foreign, Commonwealth and Development Office; DAERA NI; The Scottish Government; and the Department of Health, ROI.


Areas for discussion:

  • prevention
    • the NIHP - its role and scope, and how it will work with partners across the health system
    • building on PHE’s Infectious Disease Strategy 2020-25 - which made becoming a world leader in tackling antimicrobial resistance a strategic priority
    • learning from the COVID-19 response - for responses to future infectious diseases
  • promoting the responsible use of antibiotics in healthcare
    • responsible use of antibiotics in healthcare - progress and next steps in the context of the UK 5-year action plan
    • encouraging the appropriate use of antibiotics:
      • increasing patient awareness of AMR
      • engaging with clinicians to reduce antibiotic use to inform appropriate prescribing, including through provision of training
      • the significance of the use of nanotechnology to detect antibiotic resistance, developed by an EPSRC-funded research team
      • improving diagnostic testing of infections and utilising data
      • the impact of COVID-19 on AMR with increased use of antibiotics, including to tackle associated conditions such as sepsis and dental care
    • tackling antimicrobial resistance across local health systems:
      • implementation strategies
      • the role of antimicrobial stewardships and taking a system-wide approach in preserving antimicrobials
      • using COVID-19 recovery plans as an opportunity to integrate tackling AMR in local health systems going forward
    • animal and environmental health - assessing progress, how lessons learned can be applied to human health, and opportunities for collaboration among sectors
  • international collaboration
    • assessing the global health and pharmaceutical sector response to tackling COVID-19 and what can be learnt from the rapid vaccine development
    • opportunities for tackling antimicrobial resistance as part of the fight against the pandemic
    • what can be learnt from the global collaboration for COVID-19 that can be transferred to AMR
  • research and innovation
    • COVID-19 - the impact of tackling the pandemic on antimicrobial research systems
    • priority areas for driving forward innovation
    • regulation - opportunities for supporting and speeding up the adoption of new innovative treatment and methods
    • assessing new funding models - prospects for getting innovative clinical research adopted and bringing forward new antibiotics to benefit patients, looking at:
      • the new DHSC government payment system in making the development of new antibiotics more attractive to the pharmaceutical industry
      • the international AMR Action Fund

A scan of relevant developments:

  • the National Institute for Health Protection (NIHP) - bringing together PHE and NHS Test and Trace, as well as the analytical capability of the JBC under a single leadership team
  • the new DHSC payment model for antibiotics:
    • where pharmaceutical companies are paid up front for developing new antibiotics as a way of incentivising the development of innovative treatments
    • with payment being based on the value it provides instead of the amount consumed
  • the AMR Action Fund - launched by pharmaceutical companies around the world to tackle AMR
  • DHSC’s UK 5-year action plan for antimicrobial resistance 2019 to 2024 - including areas such as optimising prescribing, utilising data, improving education and training, and public engagement
  • the PHE infectious diseases strategy - for 2020 and 2025 with plans for the allocation of resources and tackling infectious diseases

The agenda:

  • Trends in global antibiotic use - time for increased AWaRe-ness and ambition?
  • The impact of COVID-19 on antimicrobial resistance research systems and advancing innovation
  • Next steps for enabling the development and adoption of innovation and new treatments
  • Funding and opportunities for accelerating clinical research and it reaching patients
  • The new payment system - prospects and priorities for incentivising the development of new antibiotic treatments
  • Progress in prescribing and tackling antimicrobial resistance in the UK
  • Improving prevention and understanding the impact of COVID-19
  • Applying lessons from AMR in animal and environmental health and opportunities for collaboration
  • Responsible antibiotic use in healthcare and integration with COVID-19 recovery plans - improving diagnostics and appropriate prescribing, supporting clinicians and patients, and implementation in local health systems

Policy officials attending

Our forums are known for attracting strong interest from policymakers and stake holders. Places have been reserved by parliamentary pass-holders from both Houses of Parliament and officials from DHSC; the MHRA; HM Treasury; the National Audit Office; Defra; the Department for International Trade; the Foreign, Commonwealth and Development Office; DAERA NI; The Scottish Government; and the Department of Health, ROI.


Overall, we expect speakers and attendees to be a senior and informed group including Members of both Houses of Parliament, and senior government and regulatory officials involved in this area of public policy, together with representatives from the NHS and private health providers, executive agencies including clinical staff, CCGs, pharmaceutical companies, diagnostics and medical technology companies, animal and environmental health professionals, the independent and third sectors, patient groups, local authorities, research and development organisations, law firms and consultancies, as well as academics and think tanks, and reporters from the national and specialist media.


This is a full-scale conference taking place online***

  • full, four-hour programme including comfort breaks - you’ll also get a full recording to refer back to
  • information-rich discussion involving key policymakers and stakeholders
  • conference materials provided in advance, including speaker biographies
  • speakers presenting via webcam, accompanied by slides if they wish, using the Cisco WebEx professional online conference platform (easy for delegates - we’ll provide full details)
  • opportunities for live delegate questions and comments with all speakers
  • a recording of the addresses, all slides cleared by speakers, and further materials, is made available to all delegates afterwards as a permanent record of the proceedings
  • delegates are able to add their own written comments and articles following the conference, to be distributed to all attendees and more widely
  • networking too - there will be opportunities for delegates to e-meet and interact - we’ll tell you how!

Full information and guidance on how to take part will be sent to delegates before the conference



Keynote Speakers

Dr Kitty Healey

Head, Antimicrobial Resistance Policy and Surveillance, Veterinary Medicines Directorate, Defra

Dr Colin Brown

Interim Deputy Director, Healthcare-associated Infections and Antimicrobial Resistance, National Infection Service, Public Health England

Keynote Speakers

Dr Colin Brown

Interim Deputy Director, Healthcare-associated Infections and Antimicrobial Resistance, National Infection Service, Public Health England

Dr Bryan Deane

New Medicines and Data Policy Director, ABPI

Dr Gregory Amos

Head of Microbiome Section, National Institute for Biological Standards and Control

Dr Jessica Boname

Head of Antimicrobial Resistance, Medical Research Council

Professor Mike Sharland

Professor in Paediatric Infectious Diseases, St George's University London and Chair, WHO EML Antibiotic Working Group

Silas Holland

Interim Head of External Affairs, AMR Action Fund

Professor Peter Wilson

Consultant Microbiologist, University College London Hospitals NHS Foundation Trust; and Member, Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infection

Dr Kitty Healey

Head, Antimicrobial Resistance Policy and Surveillance, Veterinary Medicines Directorate, Defra

Chair

Kevin Hollinrake MP

Speakers

Lucy Watson

Chair, The Patients Association

Dr Matthew Inada-Kim

Consultant Acute Physician, Hampshire Hospitals NHS Foundation Trust

Professor Chris Butler

General Practitioner and Professor of Primary Care, Nuffield Department of Primary Care Health Sciences, University of Oxford

Professor Graham Cooke

NIHR Professor of Infectious Diseases, Department of Infectious Disease, Imperial College London

Dr Syed Gilani

Principal Pharmacist, Antimicrobial Therapy, Dudley Group NHS Foundation Trust